Look Past The Setbacks And Give Neumora Therapeutics Inc (NASDAQ: NMRA) Another Chance

money audit

Neumora Therapeutics Inc (NASDAQ:NMRA) currently has a daily average trading volume of 3.31M but it saw 1129543 shares traded in last market. With a market cap of 178.18M USD, the company’s current market price of $1.10 came rising about 0.92 while comparing to the previous closing price of $1.09. In past 52 weeks, the stock remained buoying in the range of price level as high as $17.19 and as low as $1.08. In the recent trading on the day, stock has struck highest price mark of $1.03 while lowest mark touched by it was $1.12.

Taking a look at 20-day trading activity of Neumora Therapeutics Inc (NMRA) gives us an average price of $1.3015, while its current price level is -93.60% below from 52-week high level whereas it is 1.85% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.6444 while that of 200 days or SMA-200 reads an average of $8.7354. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.52% during that period while stretching the period over a month that increases to 9.15%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.43 which implies that the stock is in oversold territory.

Stifel downgraded its recommendation for the stock as a “Hold” from “Buy” on March 07, 2025 while assigning a price target range of $6-$2.

Over the week, NMRA’s stock price is moving -5.17% down while it is -32.10% when we observe its performance for the past one month. Year-to-date it is -89.62% down and over the past year, the stock is showing a downside performance of -91.16%.

Currently, Neumora Therapeutics Inc’s total number of outstanding shares is 161.71M. Company’s return on investment (ROI) stands at -84.92% and return on equity (ROE) at -64.48%. Stock’s beta reads 2.82. Stock has a price to book (P/B) ratio of 0.62. Its return on asset (ROA) is -59.96% on average.